Muririe neuroblastoma vaccines produced by retroviral transfer of MHC class II genes

Cancer Gene Therapy

Volumn 3, Issue 5, 1996, Pages 314-320

  Hock, Randy A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Immunotherapy; Major histocompatibility complex class ii; Neuroblastoma; Retroviral vectors

Indexed keywords

INTERLEUKIN 2; MITOMYCIN; VACCINE;

ANIMAL; ARTICLE; CELL CULTURE; CELL DIVISION; GENE; GENE TRANSFER; GENE VECTOR; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; METABOLISM; MOUSE; MOUSE STRAIN; NEUROBLASTOMA; RETROVIRUS; SPLEEN; T LYMPHOCYTE;

ANIMALS; CELL DIVISION; GENE TRANSFER TECHNIQUES; GENES, MHC CLASS II; GENETIC VECTORS; HUMANS; IMMUNIZATION; INTERLEUKIN-2; MICE; MICE, INBRED STRAINS; MITOMYCIN; NEUROBLASTOMA; RETROVIRIDAE; SPLEEN; T-LYMPHOCYTES; TUMOR CELLS, CULTURED; VACCINES;

EID: 0030226644     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. James RFL, Edwards S, Hui KM, et al. The effect of class II gene transfection on the tumourigenicity of the H-2K-negative mouse leukaemia cell line K36.16. Immunology. 1991;72:213-218.
2. Ostrand-Rosenberg S, Thakur A, Clements V. Rejection of mouse sarcoma cells after transfection of MHC class II genes. J Immunol 1990;144:4068-4071.